Abstract
Climate change and urbanization are increasing the distribution of insect vectors of infectious diseases. Dengue virus is an arbovirus that causes nearly 100 million symptomatic infections per year and is endemic in 124 countries, and the range of its mosquito vectors continues to increase. Surveillance of dengue virus infections is complicated by the fact that infections can be asymptomatic and symptoms may not be readily recognizable to clinicians. Here we show that wastewater monitoring can be used to detect dengue virus RNA to yield information about circulation of dengue infections in a community. We collected three samples of wastewater solids per week from three different wastewater treatment plants in Miami-Dade County, Florida where dengue infections have been locally acquired. Using molecular methods, we tested wastewater solids for RNA from the 4 dengue virus serotypes and consistently detected dengue virus 3 RNA at all three wastewater plants, and did not detect the other 3 serotypes. According to publicly available data on dengue infections, the vast majority of infections were caused by serotype 3. Wastewater detection of dengue virus RNA is possible with as few as 4.23 laboratory confirmed dengue cases per 1 million people, based on publicly available infection data.
Synopsis Dengue virus RNA was detected in wastewater solids in a location with local- and travel-associated dengue infections.
Competing Interest Statement
Brad White, Bridgette Shelden, and Dorothea Duong are employees of Verily Life Sciences, LLC.
Funding Statement
The research was supported by a gift from the Sergey Brin Family Foundation to ABB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: https://www.floridahealth.gov/diseases-and-conditions/mosquito-borne-diseases/surveillance.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available at the Stanford Digital Repository.
